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SUMMARY. Objective. To evaluate the effect of the hormone replacement therapy on breast changes in postmenopausal
women. Material and methods. The study includes 35 women with natural or surgical menopause who were treated with
sequential estrogen/progestogen hormone replacement therapy (E/P HRT) during one year. The therapeutic program con-
sisted of three weeks treatment with estradiol valerate 2 mg/day orally, combined with ciproterone acetate 1 mg/day in the
last 10 days (Climen© – Schering) followed by one week pause. Before the start with E/P HRT basic mammography and
ultrasound examination of the breast tissue was performed in all patients. At the end of the study after 12 therapeutic
cycles, control mammography and ultrasonographic examination were done. Results. In the short-term study 18 patients
(51.43%) showed regression of the finding, 15 (42.86%) stagnation, and only 2 (5.71%) progression of the finding (D=0.27,
p<0.01). Conclusion. A clear consensus regarding the relationship between HRT and breast cancer risk cannot yet be
drawn.
Stru~ni ~lanak
Klju~ne rije~i: hormonsko nadomjesno lije~enje, estrogeni, progestogeni, dojka, mamografija, ultrazvuk
SA`ETAK. Cilj rada je bio vrednovati u~inak hormonskog nadomjesnog lije~enja na promjene dojke u 35 `ena u post-
menopauzi. Bolesnice i na~in istra`ivanja. 35 `ena u prirodnoj ili kirur{koj postmenopauzi je kroz jednu godinu lije~e-
no sekvencijskom hormonskom nadomjesnom terapijom (HNL). Terapijska shema je bila tri tjedna estradiol valerijanat
2 mg/dan peroralno, kombinirano s ciproteron acetatom 1 mg/dan posljednjih 10 dana (Climen© – Schering) te nakon toga
sedam dana stanke. Prije po~etka HNL svima je pacijenticama u~injena mamografija i ultrazvu~ni pregled dojki. Na kraju
studije, nakon 12 terapijskih ciklusa, u~injeni su kontrolna mamografija i pregled ultrazvukom. Rezultati. U kratkoro~noj
studiji u 18 pacijentica (51,43%) nastupila je regresija nalaza, u 15 (42,86%) stagnacija i u 2 (5,71%) pacijentice progresija
nalaza (D=0,27, p<0,01). Zaklju~ak. Jasni dogovor u pogledu odnosa izme|u hormonskog nadomjesnog lije~enja i raka
dojke jo{ se ne mo`e donijeti.
Introduction
Breast cancer is one of the most frequent cancers in
the female population. Approximately one of every 10–
12 women will develop this type of cancer during her
life, its incidence is highest in the premenopausal period.
More than 25 % of all cases of breast cancer occurred
before 50 years of age.1 Although there are more diffe-
rent theories explaining the connection between the fe-
male sexual hormones and the risk of breast cancer, the
specific role of the estrogens and progestogens in this
process have never been cleared enough. Estrogens sti-
mulate the breast tissue through their own estrogen re-
ceptors and the effect of this stimulation is a prolifera-
tion of the ductal and alveolar epithelium. Estrogen re-
ceptor-transmission mechanisms are shown as regula-
tors of the effects of many different substances, such as:
transforming growth factor alfa, transforming growth
factor beta, enzymes (cathepsin D, and plasminogen ac-
tivator), prooncogenes (c-fos, C-mis i HER-2/neu). As a
result, the value of mRNK increases several hours after
the estrogen administration.1 Progesterone in the second
part of the menstrual cycle induces dilatation of the duc-
tal system and secretory transformation of the alveolar
cells; in the menstrual phase there is some exfoliation of
the alveolar cells, similar to those of the endometrium.
Progestogens regulate estrogen receptors on a very low
level, so they interfere with estrogen receptor transmis-
sion activity on proto-oncogenes. The ratio of the two
progesterone receptor isoforms, PRA/PRB may define
the response to progesterone in breast tissue. Isaksson
and al.2 measured the immunohistochemical expression
of PRA and PBA in postmenopausal cynomolgus maca-
cas, treated for 35 months with conjugated equine estro-
gens (CEE), tamoxifen or medroxyprogesterone acetate
(MPA, CEE + MPA) and found: unchanged levels of PRA
in CEE and a decline in the CEE/MPA group. The mean
PRA/PRB in the CEE group was 2,7, and in CEE/MPA
group 0,2.
Syndrome of fibrocystic breast (Reclus-Cooper’s dis-
ease) is a benign disease. The first stage of development
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of the disease is mastodynia with cyclic premenstrual
symptoms and histological feature of oedema and pro-
liferation of the perilobular fibrose tissue. If progeste-
rone is given, symptoms disappear or are reducing. The
second stage is a stage of pseudotumor, when the pain is
not so intense, but a rough nodular stucture, benign or
atypical hyperplasia of the ductal and lobular epithelium
and fibrous stromal proliferation are present. The third
stage is a presence of cysts, who are the result of ductal
system obstruction due to fibrous stromal or intraductal
proliferation. Microcystic disease is present when cysts
are smaller than 20 mm in diameter, and macrocystic
mastopathy when they are larger. Investigating the rela-
tionship between HRT and frequency of breast atypical
hyperplasia, Gayet and al.3 found the incidence rate sig-
nificantly increased over time and significantly higher
for HRT users (Odds Ratio 2.05), partly by the incidental
discovery of these lesions by mammography and partly
by a real increase of the disease.
Regarding the possible connection between hormone
replacement therapy (HRT) and breast cancer, the anal-
yses show that the relative risk is approximately 1,08 to
1,30, but there are almost the same number of studies
showing insignificant reduction of the risk of breast can-
cer during HRT.4 Most authors agree that women who
have taken HRT less than 5 years, don’t have any risk of
breast malignomas. On the other hand, there are differ-
ent attitudes if the HRT is taken more than 5 years. The
Women’s Health Initiative trial5 of combined estrogen
plus progestin therapy (conjugated equine estrogens
0,625 mg/day and MPA 2,5 mg/day) found increased total
hazard ratio 1,24 of invasive breast cancer compared with
placebo. Seeger and al.,6 investigating in vitro the influ-
ence of the three most used progestogens: MCA, nore-
thisterone acetate (NET) and progesterone (P) on the
human breast cancer cell line MCF-7 found that all these
progestogens, given alone, displayed a significant inhi-
bition of cell proliferation, and in combination with es-
tradiol this inhibitory effect is lower, but still significant.
It is not yet clear whether there is a difference in risk
with sequentially combined versus continuously combined
HRT. Seeger and al,7 investigating the influence of pro-
gesterone and various synthetic C-19 and C-21 progestins
on cell proliferation of a human breast cancer cell line in
vitro, found that sequentially combined with estradiol,
only chlormadinone acetate showed significant inhibi-
tory effect on cell proliferation. Continuously combined,
all progestins exhibited this inhibitory effect.
At the beginning of the 21st century, mammography
screening is still the most important diagnostic method
in the early recognition of breast cancer. Its advantage is
in its ability to detect calcifications in the inpalpable forms
of carcinomas and providing a precise information about
disposition of the mammary structures, especially in the
involutive postmenopausal breasts. X-rays passing through
the breast tissue are being absorbed from the fibro-glan-
dular elements, and we see a ’shadow’ on mammogra-
phy, whose density depends of the percentual portion of
these elements. Greater quantity of connective and glan-
dular tissue give higher density of the shadow. In oppo-
site, fat tissue is much more permeable for X-rays and it
is projected like transparent zone on mammography. Ac-
cording to the Wolf’s classification the mammographic
pictures can be classified as: N1 – predominatly fat tissue
without galactofores; P1 – ductal picture is present in
less than the fourth of the breast tissue; P2 – nodular and
ductal parenchima in more than the fourth of the breast
tisssue; DY – diffusely increased density of the breast
tissue (fibrocystic disease). The aging process which is
most distinctive in the postmenopausal period leads to
atrophy of ductal and glandular structures which are re-
placed with fat tissue. HRT can change this process of
aging in the breasts and can also increase the density of
the breast tissue.
Material and methods
The study was designed according to the CONSORT
statement.8
1. Eligibility criteria for participants: 1. At least one-
year long postmenopausal period, e.g. period between
last menstrual cycle and date of admitting at the Outpa-
tient Department for Menopause in patients with natural
menoapause; or previous hysterectomy with bilateral
oophorectomy in a period of one month to five years be-
fore admission at our Department in patients with surgi-
cal menopause; 2. Patient’s age less than 55 years; 3.
Absence of some contraindication for hormone replace-
ment therapy, as follows: otosclerosis, cholelithiasis, pre-
sence of serious liver or kidney damage, familiar history
of breast cancer, personal history of breast, endometrial
or ovarian cancer, the actual trombophlebitis or phle-
bothrombosis.
2. The setting, location and timing where and when
the date were collected: the Outpatient Department for
menopause of the Clinic of Gynecology and Obstetrics,
Medical Faculty, Skopje in the period from the 1st of Ja-
nuary 2002 to the 1st of April 2003.
3. Precise details of the interventions for the group,
how and when they were actually administered: All pa-
tients were treated with oral sequential estrogen/proge-
stogen hormone replacement therapy (OSeq E/P HRT)
during one year. The therapeutic scheme consisted of three
weeks treatment with estradiol valerate 2 mg/day orally,
combined with ciproterone acetate 1mg/day in the last
10 days (Climen® – Schering) followed by one-week
pause. This drug has been approved by the Republic Drug
committee (RDC) of the Republic of Macedonia.
4. specific objectives and hypotheses: The purpose of
the study was an assessment of the safety of the 28-day
regimen with Seq E/P HRT with Climen® during one year
regarding breast tissue. The hypothesis was: this HRT
regimen has not any serious adverse effects on the breast.
5. Clearly defined primary and secondary outcome
measures, any methods used to enhance the quality of
measurements:
Before the therapy, the evaluation of all women in-
cluded:
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1. A standardized structured protocol questionnaire for
menopause designed according to the recommenda-
tions by the Europian Society for Menopause, which
include:
Demographic data (Table 1.): age, duration of the
postmenopausal age, parity, smoking habits and al-
cohol consuming, sport, diet, body mass index, sys-
tolic/diastolic blood pressure, type of menopause
Table 1. Demographic data: age, duration of the postmenopause, parity,
smoking habits and alcohol, body mass index, systolic/diastolic blood pres-
sure, type of menopause (natural, surgical) in 35 postmenopausal patients
Tablica 1. Demografski podaci: dob, trajanje postmenopauze, paritet, na-
vike pu{enja i pijenja alkohola, indeks tjelesne te`ine, sistoli~ki/dijastoli~ki
krvni tlak, vrsta menopauze (prirodna, kirur{ka)
Age (years) 47.52±3.7
Dob (godine)
Duration of the postmenopause (months) 29±6.20
Trajanje postmenopauze (mjeseci)
Parity – Paritet 2 (0 to 5)
Smokers – Pu{a~ice 10/35
Alcohol consumers 2/35
Potro{a~ice alkohola
Body mass index (BMI) 27.81±3.84
Indeks tjelesne te`ine
Systolic / Diastolic 92.23±11.20 / 146.11±24.60
blood pressure (mmHg)
Sistoli~ki/Dijastoli~ki krvni tlak
Natural / Surgical menopause 9/35 / 26/35
Prirodne / Kirur{ke menopause
Table 2. Kupperman’s postmenopausal index
Tablica 2. Kuppermanov postmenopauzalni indeks
Factors/points Absent Mild Moderate Intensive Unbearable Points
Nema Blagi Umjereni Jaki Nepodno{ljivi Bodovi
Hot flashes – Vru}i valovi 0 4 8 12 16
Paresthesia – Trnci 0 2 4   6   8
Insomnia – Nesanica 0 2 4   6   8
Nervousness – @iv~anost 0 2 4   6   8
Depression – Poti{tenost 0 1 2   3   4
Vertigo – Vrtoglavica 0 1 2   3   4
Fatigue – Umor 0 1 2   3   4
Joint pain – Zglobne boli 0 1 2   3   4
Headache – Glavobolja 0 1 2   3   4
Palpitation – Lupanje srca 0 1 2   3   4
Climax Sum:
mild: sum 15–20 points – blagi: zbroj 15–20 bodova Zbroj:
moderate: sum 21–35 points – umjereni: zbroj 21–35 bodova
grave: sum >35 points – te{ki: zbroj >35 bodova




 body height (cm)2
Kupperman index for the menopausal symptoms as-
sessment, represented on the Table 2.
Familiar history for coronary disease, osteoporosis,
breast cancer, colorectal cancer or endometrial can-
cer, Alzheimer sclerosis, cerebrovascular insult (ta-
ble 3.).
Personal history for previous or present diseases,
such as: coronary disease, hepatic or kidney disease,
therapy with corticosteroids, thyroid gland disease,
postgastrectomy malabsorption syndrom, Cushing’s
disease, thromboembolism or phlebothrombosis,
osteoporotic fracture, breast cancer, genital cancer,
colorectal cancer, otosclerosis, cholelithiasis, genital
prolapse, urine incontinence, hyperparathyroidism
and history for present sexual life: dyspareunia, de-
crease of the libido, absent orgasm (Table 4.).
2. Complete evaluation for possible contraindications
for HRT: 1. Abdominal ultrasound for excluding:
cholelythiasis, hepatic damage (cirrhosis, hepatic
metastases), abdominal tumors; 2. Complete labo-
ratory analyses for hepatic and kidney function, such
Table 3. Family history in 35 postmenopausal patients
Tablica 3. Obiteljska anamneza u 35 postmenopauzalnih bolesnica
Coronary disease – Koronarna bolest 12 – 34.3%
Osteoporosis – Osteoporoza 11 – 31.4%
Breast cancer – Rak dojke   1 –   2.9%
Colorectal cancer – Kolorektalni rak   3 –   8.6%
Endometrial cancer – Rak endometrija   1 –   2.9%
Alzheimer disease – Alzheimerova bolest   5 – 13.5%
Cerebrovascular insult – Cerebrovaskularni inzult   6 – 17.1%
as: alkaline phosphatase, acid phosphatase, ALT,
AST, LDH, serum urea, serum creatinin, serum uric
acid; 3. some parameters of the coagulation status,
such as:prothrombin time (PT) that is expressed into:
absolute value, percentage and INR; activated par-
tial thromboplastin time (aPTT Pathrombin SL);
thrombin time and platelets number; 3. complete
gynaecological evaluation, including: cervical smear
and colposcopy, gynaecologic ultrasound of the pel-
vis for excluding uterine and ovarian tumors, and
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Table 4. Personal history for previous or present diseases and for sexual
life (n=35)
Tablica 4. Osobna anamneza za prethodne ili aktualne bolesti i za aktualni
seksualni `ivot (n=35)
Coronary disease – Koronarna bolest   3 –   8.6%
Hypertension – Hipertenzija 14 – 40.0%
Thyroid gland disease – Bolest {titnja~e   2 –   5.7%
Diabetes mellitus – [e}erna bolest   6 – 17.1%
Previous thrombosis – Ranija tromboza   3 –   8.6%
Genital prolapse – Ispadanje genitala   5 – 14.3%
Stress incontinence – Stres inkontinencija   9 – 25.7%
Osteoporosis (ultrasound BDM of calcaneus   7 – 20.0%
decreased more than 2SD)
Dyspareunia – Dispareunija 15 – 42.9%
Decrease of the libido – Smanjen libido 29 – 76.3%
Absent orgasm – Nepostojanje orgazma 26 – 74.3%
Table 5. Sexual life (absence of orgasm) at the beginning and at the end of
the study in three groups of 35 postmenopausal patients
Tablica 5. Spolni do`ivljaj (orgazam) na po~etku i kraju studije u tri sku-
pine 35 postmenopauzalnih bolesnica
Absent orgasm – Nepostojanje orgazma
At the beginning At the end
of the study of the study
Na po~etku studije Na kraju studije
Mild – Blagi 7/35 (20%) 5/35 (14.3%)
climax
Moderate – Umjeren 15/35 (42.9%) 3/35 (8.6%)
climax
Grave – Te{ki 13/35 (37.1%) 1/35 (2.9%)
climax
evaluation of the thickness of endometrium. The thi-
ckness of the endometrium more than 4 mm was
indication for its histological evaluation. All the pa-
rameters were determined at the beginning, on the
sixt month and at the end of the study.
3. Breast tissue evaluation with mamography (Wolf’s
classification): N1 – predominantely fat tissue with-
out galactofores; P1 – ductal picture is present in
less than fourth of the breast tissue; P2 – nodular and
ductal parenchim in more than fourth of the breast
tisssue; DY – diffusely increased density of the brast
tissue (fibrocystic disease).
At the end of the study, after one-year Seq E/P HRT,
the evaluation of all women included:
– Kupperman index for the menopausal symptoms as-
sessment;
– Complete laboratory analyses for hepatic and kidney
function;
– Same parameters of the coagulating status;
– Complete gynecologic evaluation as quoted previou-
sly;
– Breast tissue evaluation with mamography ( Wolf’s
classification).
The determination of the definitive sample size.
Every fifth postmenopausal patient admitted at the Out-
patient Department for Menopause in the period was
assessed for eligibility for this HRT regiment with Cli-
men (n=57). Seven patients were excluded from the study
because they refused to participate, and eight stopped
the therapy prematurely, before one year duration. So,
forty two patients were randomised. Nine of them were
excluded because of the presence of some contraindica-
tion for HRT: three with previous history of breast can-
cer, one with previous endometrial cancer, three with pres-
ence of biliar calculosis and two with great disturbance
of hemostasis, like elevated plasminogen inhibitors and
decreased protein C and protein S.
Every fifth postmenopausal patient was allocated into
the study group according to the admission date.The se-
quence was discontinued when a patient was excluded
because of some reasons. The authors of this study deter-
mined the allocation sequence, enrolled participants, as-
signed participant to this group. All participants were
aware of group assignment. All subjects were given an
explanation of the study and informed consent was ob-
tained. Women who were unhappy to be randomized were
excluded.
Statistic analysis was made using Student’s t test and
Kolmogarof-Smirnof test for one study group.
Results
Kupperman index for the menopausal symptoms dur-
ing the study is represented on the table 5. The absence
Table 6. Coagulation status at the beginning and at the end of the study
(n=35)
Tablica 6. Koagulacijski status na po~etku i na kraju studije (n=35)
Parameter Before therapy After therapy t p
Pokazatelj Prije terapije Poslije terapije
Prothrombin time 10.52±2.16 10.62±2.23   0.137 NS
PT %   92.64±14.65   89.36±12.66   0.221 NS
PT INR   1.03±0.18   1.05±0.22   0.417 NS
aPTT Pathtrombin 26.66±2.23 28.19±4.47   1.789 NS
Thrombin time 13.27±1.97 15.22±1.25 14.889 <0.0001
Thrombocytes 293.33±65.18 244.22±58.15   3.283 <0.002  
Table 7. Cervical Pap smear and colposcopic findings
Tablica 7. Cervikalni obrisak po Papanicolaou i kolposkopski nalaz
Pap smear – Papa Obrisak
Atrophic smear with candida infection 15 – 42.9%
Atrofi~ni razmaz s kvasni~kom infekcijom
Atrophic smear with nonsepcific infection 10 – 28.6%
Atrofi~ni razmaz s nespecifi~nom infekcijom
Atrophic smear with coilocytosis   3 –   8.6%
Atrofi~ni razmaz s koilocitozom
Atrophic smear without infection 16 – 45.7%
Atrofi~ni razmaz bez infekcije
Colposcopy – Kolposkopija
Unvisible zone of transformation 16 – 45.7%
Nevidljiva transformacijska zona
Leucoplakia   5 – 14.3%
(biopsia: 3 parakeratosis, 2 hyperkeratosis,
1 coilocytosis)
Normal colposcopic pattern   8 – 22.9%
Normalna kolposkopska slika
Mozaic – Mozaik   1 –   2.0%
Ectopia   5 – 14.3%
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of the orgasm was more prominent in the cases of mod-
erate and grave climax, it has been ameliorated in most
of them.
In all patients who finished the study (n=35) there were
no contraindication for HRT. The laboratory examina-
tions were in normal range at the beginning of the study,
on the sixth month and at the end of the study.
The evaluated parameters of the coagulation status did
not change, except the thrombin time and platelets number
that significantly decreased (Table 6.).
The gynecological ultrasonography of the pelvis for
excluding uterine and ovarian tumors, and evaluation of
the endometrial feature, performed at the beginning of
the study, on the sixth month and at the end of the study
was normal. The thickness of the endometrium more than
4 mm in 5 out of 35 patients at the beginning of the ther-
apy was indication for its histological evaluation. In all
four cases the hystological was »matron« polyp with
atrophic endometrium.
Cervical smear and colposcopic findings at the begin-
ning of the study are represented on the Table 7. A usual
distribution of abnormal patterns can be seen.
On the Table 8. the mammographic findings and ul-
trasonographic examination of breast tissue in 35 users
of one-year sequentional estrogen/progestagen hormone
replacement therapy (Climen-Schering), before and after
the therapy, are presented. As can be seen at the end of
the study there were 18 cases (18/35, i.e. 51,43%) of
regression, 15 cases (15/35, i.e. 42,86%) of stagnation
and 2 cases (2/35, i.e. 5,71%) of progression in findings.
In the group with regression in 3 patients the dimen-
sions of conglomerates became significantly smaller; in
5 the conglomerates disappeared completely; in 7 patients
with regular findings or mastopathy at beginning of the
study, there was an involutive feature at the end; in 3
patients with fibrocystic disease a significant reduction
or disappearing of this condition was noticed at the end
of the study.
Only two cases (2/35, v.s. 5,71%) had progressive tis-
sue changes at the end of the study. In the first case with
massive conglomerate, there was an evolution in the cir-
cumscriptive tumor with benign cytology. In the second
case, a retromammilar fibrosis occurred.
Statistical analysis using Kolmogarof-Smirnof test for
a study group is as follows (Table 9.).
Table 8. Mammographic findings and ultrasonographic examination of
breast tissue in 35 users of one-year sequentional estrogen/progestagen
hormone replacement therapy
Tablica 8. Mamografski i ultrazvu~ni nalazi 35 korisnica jednogodi{nje
sekvencijske estrogen/progestagenske nadomjesne terapije
Findings before Findings after Progression
Patient therapy therapy Regression
Pacijentica Nalaz prije Nalaz nakon Stagnation
terapije terapije
  1. M. D. P1 P1 St
  2. T. Z. P1 N1 Reg
  3. S. E. DY N1 Reg
  4. J. R. P2 DY Prog
  5. S. M. N1 N1 St
  6. K. A. P1 P1 St
  7. Z. L. DY DY St
  8. N. S. P1 N1 Reg
  9. S. V. P1 N1 Reg
10. A. S. DY P1 Reg
11. M. Lj. P2 P2 St
12. I. M. P1 N1 Reg
13. S. B. P2 P1 Reg
14. I. A. P1 N1 Reg
15. J. N. P1 P1 St
16. M. M. DY P1 Reg
17. A. M. P2 P1 Reg
18. A. M. P1 P1 St
19. D. V. DY P2 Reg
20. S. V. P2 P1 Reg
21. S. D. DY DY St
22. S. S. P1 N1 Reg
23. D. E. DY P1 Reg
24. G. L. DY P2 Reg
25. L. Lj. P1 P1 St
26. P. Lj. P2 P2 St
27. H. A. N1 P1 Prog
28. K. M. P1 P1 St
29. D. S. DY DY St
30. B. D. P2 N1 St
31. S. S. P2 P2 St
32. K. A. P2 P1 Reg
33. J. R. P2 P1 Reg
34. N. L. P1 P1 St
35. R. A. DY DY St
N1: predominantely fat tissue without galactofores
prete`no masno tkivo bez galaktofora
P1: ductal picture is present in less than fourth of the breast tissue
pojava duktusa u manje od ~etvrtine tkiva dojke
P2: nodular and ductal parenchima in more than fourth of the breast tissue
nodularni i duktalni parenhim u vi{e od ~etvrtine tkiva dojke
DY: diffusely increased density of the breast tissue (fibrocystic disease)
difuzno pove}ana gusto}a tkiva dojke (fibrocisti~na bolest)
Table 9. Statistic analysis of the mamographic findings and ultrasonographic examination of breast tissue in 35 users of HRT
after one-year long therapy with Climen
Tablica 9. Statisti~ka analiza mamografskih i ultrazvu~nih nalaza 35 korisnica nakon jednogodi{nje sekvencijske estrogen/pro-
gestagenske nadomjesne terapije Climenom
Relative Relative Cumulative Cumulative D p
Regression 18 11.67 18/35 = 0.51 11.67/35 = 0.33 18/35 = 0.51 11.67/35 = 0.33 0.18
Stagnation 15 11.67 15/35 = 0.43 11.67/35 = 0.33 33/35 = 0.94 23.34/35 – 0/67 0.27
Progression   2 11.67   2/35 = 0.06 11.67/35 = 0.33 35/35 = 1.00      35/35 = 1.00 0.00
Total 35 35     1.00 1.00
For n=35 and D=0.27 the Kolmogarof-Smirnof test for one study group is with significance of p<0.01
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Discussion
The growth of mammary tissue depends on the deli-
cate balance between the activity of the two sex steroid
hormones: estradiol and progesterone. Though the estro-
gens are the most potent stimulating factor for breast cell
proliferation, the role of progestesterone is still the sub-
ject of professional debates. Progestins could have a posi-
tive, moderate or no effect or even an inhibitory effect
on the growth of glandular tissue.
According to Lauritzen,9 the cyclic application of pro-
gestin might have double effects: to stop the prolifera-
tion and induce a specific function of target tissue, effects
which are mediated through the reduction of the estrogen
receptors in breast glandular tissue, the stimulation of
the transformation of the more potent estradiol into the
less effective estron and through the reduction of the in-
tracellular metabolism and blood supply. Women who
recieved long-term estrogen/progestagen replacement
therapy have decreased risk for development of endome-
trial and ovarian cancers, when they are compared with
untreated population. Perhaps this mechanism has to be
considered for breast cancers. On the other hand, post-
menopausal women who take long-term replacement es-
trogen/progestagen therapy, have a better prognosis (with
statistical significance) of breast or genital cancers occur-
red during the treatment, in comparision with untreated
women.
According to Gornis and Denis10 there is a possibility
that distinctive progestagens have distinctive effects.
Therapeutical use of progestagens is based on the pitui-
tary-ovarial supression mechanism. It is not clear whether
they are protective for breast cancer. If this is true, are
there different mechanisms in their protective action on
the mammary glandular cells and on the endometrial
cells? They act on the endometrium by maintenance of
low level of estrogen receptors with increase of 17-beta
hydroxysteroid dehydrogenase activity.
Cahn and al11 conducted a retrospective study of 156
female patients who had benign breast lesion. Fifty seven
of them had a tissue biopsy which prelude further devel-
opment of breast carcinoma, like sclerosanting adeno-
sis, intraductal papilloma and atypical epithelial hyper-
plasia. Almost 63% of these 57 (v.s. 36 patients), recived
hormonal replacement therapy (HRT). The other 99 out
of total 157 patients had nonproliferative lesions. Thirty
patients of them also recived HRT. From the results, the
authors concluded that the use of HRT could cause de-
velopment of lesions, leading to breast carinoma.
A special comparative study was done by Kaufman
and al.12 The data from 1686 selected patients were com-
pared with 2077 hospital control cases, from which 1120
were with nongenital cancers and 957 with nonmalig-
nant disease.The data were collected through interviews
in the period from 1980 to 1986. The results from this
study didn’t prove proposition that the use of nonoppo-
nent conjugated estrogens could increase the risk for
breast cancer, even if they have been used for a long
period. This study is insufficient for evaluation of the
effect of nonconjugated estrogen and combined estro-
gen/progestagen therapy.
The biggest published double blind control study
(Nachtigall),13 showed that the number of breast carci-
nomas among the users of HRT was lower than in the
placebo group, with a statistical significance. The recent
Nurses Health Cohort Study14 showed a relatively in-
creased risk (1,32) for breast carcinomas in users of es-
trogen HRT and 1,41 in combined estrogen/progestogen
HRT users. Standford15 reports decreased risk for breast
carcinoma in patients treated with long-term combined
HRT. During the estimation of the relationship between
the consumption of progestogens and incidence of breast
cancer, a significantly lower incidence of this cancer is
found in France opposite to the USA.These facts could
be explained with higher consumption of progestogens
in a long period in all West European countries.
Li Ci and al16 in their population-based case-control
study of 975 women 65–79 years of age with invasive
breast cancer and 1007 population control found that
women using unopposed estrogen HRT even for 25 years
or longer, had no appreciable increase in risk of breast
cancer, but ever users of combined HRT(CHRT) had a
1,7-fold(95% CI) increased risk of invasive breast can-
cer, especially in those with longer durations.
Prolonged exposure to estrogens slightly increases the
risk of breast cancer. Questions that so far not complete-
ly answered are as following: are estrogens tumor pro-
motors and accelerators of the clinically occult pre-ex-
isting tumors or they are genotoxic mutagenic carcino-
gens which initiate tumors by way of accumulation of
DNA-replication damage mechanism? The action of dif-
ferent progestogens on the estrogen-induced cellular mi-
tosis could vary from the estrogen receptor downregula-
tion, activating or stimulating apoptosis. It is not clear
whether there is a difference in risk with sequentially
combined versus continuously combined HRT. Accord-
ing to Eden,17 although the recent Women’s Health Initi-
ative trial showed a small increase in the risk of invasive
breast cancer in women undergoing therapy for 5 years
or more, a clear consensus regarding the relationship
between HRT and breast cancer risk cannot yet be drawn.
Studies have consistently documented that HRT use is
associated with improved mortality and survival rates
for women with breast cancer. Large-scale, randomized
studies on different progestin regimens are needed to
critically assess the effect of progestin on breast cancer.
Conclusion
In our short-term study of the hormone replacement
therapy with estrogens/progestogens in 35 post-menopau-
sal women, the mammographic findings predominantly
manifested the regression or stagnation of the breast
changes.
A clear consensus regarding the relationship between
HRT and breast cancer risk cannot yet be drawn.
Large scale, randomized studies on different progesto-
gen regimens to assess its effect on breast changes are
needed.
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